Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830453 · ClinicalTrials.gov registry record · Phase 2
Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury
A Phase 2 study, sponsored by Intermountain Health Care.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00830453: Completed Phase 2 study, sponsored by Intermountain Health Care.
NCT00830453 is a Phase 2 study that has completed, run by Intermountain Health Care. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00830453, a Phase 2 study, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to discover the feasibility of conducting clinical research in individuals with chronic sequelae following brain injury who are given hyperbaric oxygen. This study will also look at the outcome of individuals with a chronic stable brain injury due to trauma, anoxia (lack of oxygen to the brain), or stroke, who are given hyperbaric oxygen. Outcome measures testing cognitive (memory, etc.) and functional (balance, strength, etc.) measures will be performed before the hyperbaric sessions, immediately following them, and 6 months later. The subject will receive 60 hyperbaric sessions, 60 minutes in the chamber, to a pressure of 1.5 ATA, once daily, Monday through Friday.
Interventions
- PROCEDURE Hyperbaric oxygen therapy (HBO2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2003-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00830453 record still lists
NCT00830453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which Hyperbaric oxygen therapy (HBO2) is the first listed.
NCT00830453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00830453 about?
NCT00830453 is a clinical study titled "Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury". The purpose of this study is to discover the feasibility of conducting clinical research in individuals with chronic sequelae following brain injury who are given hyperbaric oxygen. This study will also look at the outcome of individuals with a chronic stable brain injury due to trauma, anoxia (lack...
What is the current status of trial NCT00830453?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2003-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00830453?
The interventions under investigation include: Hyperbaric oxygen therapy (HBO2) (PROCEDURE).
Who is sponsoring clinical trial NCT00830453?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00830453's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia